Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Ensem Therapeutics Inc.

Headquarters: Waltham, MA, United States of America
Year Founded: 2021
Status: Private

BioCentury | Apr 18, 2024
Product Development

CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?

AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
BioCentury | Nov 21, 2023
Deals

Nov. 21 Quick Takes: Merck buying neurology play Caraway

Plus: Simcere takes Greater China rights to Connect’s IL-4R program, and updates from BeiGene, Ensem, J&J, Genmab, Alto, Ascendis and more
BioCentury | Jun 6, 2023
Management Tracks

Jin promoted to CEO at Ensem

Plus: Pedranti named CEO at Visgenx, and updates from Altoida, Vaxxas, Variant, Immodulon and Google Ventures
BioCentury | Apr 8, 2022
Product Development

April 7 Quick Takes: ENSEM launches with $67M series A and molecular dynamics platform

Plus Viz.ai raises $100 M, MoonLake debuts on NASDAQ, and updates from
Items per page:
1 - 4 of 4